The history of Sildenafil presents a complex case for observers in the medicinal sector. While initially a phenomenal success, creating huge profits, the intellectual property end and the subsequent arrival of off-brand alternatives have significantly affected revenue. This poses questions about the ongoing viability of related medication innovatio